Singapore, July 4 -- Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs,has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co.

Joincare Group will obtain an exclusive license fromBrii Biofor the research, development, and commercialisation of BRII-693 in theGreater Chinaregion.

Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialisation of BRII-693 inGreater China. In return,Brii Biohas received an upfront payment and will receive additional development and commercial milestone payments upon certain ...